Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
RESEARCH TOOLSreports
Corvus Pharmaceuticals (CRVS) Stock Price & Analysis
483 Followers
CRVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.05 - $3.16
Previous Close$1.82
Volume85.14K
Average Volume (3M)218.08K
Market Cap
$113.84M
Enterprise Value$92.76M
Total Cash (Recent Filing)$22.13M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 01, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding62,551,281
10 Day Avg. Volume218,821
30 Day Avg. Volume218,079
Standard Deviation0.35
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-72.24
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.69
Forecast
1Y Price Target
$5.75Price Target Upside215.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Corvus Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCiforadenant passed its pre-specified efficacy threshold in front-line renal cell cancer, showing a 50% improvement on the standard of care.
Financial PerformanceCRVS successfully raised ~$30mn, extending the company's cash runway into 4Q25.
Product DevelopmentEncouraging signs of progress for soquelitinib, an ITK inhibitor that is the company's most advanced asset.
Bears Say
Clinical DataA slight push in the timing of the announcement of clinical data for ciforadenant.
Clinical TrialsA slight delay in the timing of the Phase 3 study initiation for lead asset soquelitinib.
Financial HealthThe current cash runway remains a concern.
---
Ownership Overview
39.23% Insiders
3.46% Mutual Funds
24.68% Other Institutional Investors
32.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRVS FAQ
What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?
Corvus Pharmaceuticals Inc lowest stock price was $1.05 and its highest was $3.16 in the past 12 months.
What is Corvus Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?
Corvus Pharmaceuticals Inc’s upcoming earnings report date is Aug 01, 2024 which is in 25 days.
How were Corvus Pharmaceuticals Inc’s earnings last quarter?
Corvus Pharmaceuticals Inc released its earnings results on May 06, 2024. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.015.
Is Corvus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc pay dividends?
Corvus Pharmaceuticals Inc does not currently pay dividends.
What is Corvus Pharmaceuticals Inc’s EPS estimate?
Corvus Pharmaceuticals Inc’s EPS estimate is -$0.12.
How many shares outstanding does Corvus Pharmaceuticals Inc have?
Corvus Pharmaceuticals Inc has 62,551,280 shares outstanding.
What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went down -12.042%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?
Among the largest hedge funds holding Corvus Pharmaceuticals Inc’s share is Towerview Llc. It holds Corvus Pharmaceuticals Inc’s shares valued at 681K.
---
Corvus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.75 (215.93% Upside)
$5.75 (215.93% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 54.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.79%
12-Months-Change
Fundamentals
Return on Equity
-60.46%
Trailing 12-Months
Asset Growth
-31.12%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
---
CRVS Earnings Call
Q1 2024
0:00 / 0:00
---
CRVS Stock 12 Month Forecast
Average Price Target
$5.75
▲(215.93% Upside)
Technical Analysis
Best Analysts Covering CRVS
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+4.14%
assigned a buy rating 2 months ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +4.14% per trade.
---